Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells - PubMed (original) (raw)
Affiliations
- PMID: 2851034
Comparative Study
Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells
G Soma et al. J Biol Response Mod. 1988 Dec.
Abstract
Eight species of novel recombinant tumor necrosis factor-S (rTNF-SAM group) were constructed in which N-terminal amino acid sequences were based on that of TNF-S from THP-1 cells with higher basicity than conventional rTNF-alpha. Two of this rTNF-SAM group, denoted as rTNF-SAM1 and rTNF-SAM2, showed more cytocidal activity on A549 lung carcinoma cells and G401 Wilm's tumor cells than did rTNF-alpha. In addition to these cell lines, rTNF-SAM1 revealed strong cytocidal activity on T24 bladder carcinoma cells, which are resistant to rTNF-alpha. Moreover, possible cachectin activity of rTNF-SAM2 seemed to be lower than that of conventional rTNF-alpha, suggesting that rTNF-SAM2 has less side effects. Actually, toxicity as expressed by LD50 value of rTNF-SAM2 as well as others of the rTNF-SAM group was significantly lower than that of conventional rTNF-alpha. Thus, newly constructed rTNF-SAM1 and rTNF-SAM2 should be more promising antitumor reagents for clinical use, since they were shown to be superior to conventional rTNF-alpha both in antitumor effect and in less side effects.
Similar articles
- Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-alpha in vivo.
Gatanaga T, Noguchi K, Tanabe Y, Inagawa H, Soma G, Mizuno D. Gatanaga T, et al. J Biol Response Mod. 1989 Jun;8(3):278-86. J Biol Response Mod. 1989. PMID: 2746298 - TNF induces endogenous TNF in vivo: the basis of EET therapy as a combination of rTNF together with endogenous TNF.
Inagawa H, Oshima H, Soma G, Mizuno D. Inagawa H, et al. J Biol Response Mod. 1988 Dec;7(6):596-607. J Biol Response Mod. 1988. PMID: 3216223 - Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
Lejeune F, Liénard D, Eggermont A, Schraffordt Koops H, Rosenkaimer F, Gérain J, Klaase J, Kroon B, Vanderveken J, Schmitz P. Lejeune F, et al. J Cell Biochem. 1994 Sep;56(1):52-61. doi: 10.1002/jcb.240560110. J Cell Biochem. 1994. PMID: 7806592 Review. - A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors.
Nakamoto T, Inagawa H, Takagi K, Soma G. Nakamoto T, et al. Anticancer Res. 2000 Nov-Dec;20(6A):4087-96. Anticancer Res. 2000. PMID: 11131677 Review.
Cited by
- Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication.
Matsuyama T, Hamamoto Y, Soma G, Mizuno D, Yamamoto N, Kobayashi N. Matsuyama T, et al. J Virol. 1989 Jun;63(6):2504-9. doi: 10.1128/JVI.63.6.2504-2509.1989. J Virol. 1989. PMID: 2470917 Free PMC article. - Biological activity of mutants of human tumour necrosis factor-alpha.
Kircheis R, Milleck J, Korobko VG, Shingarova LN, Behnke D, Schmidt HE. Kircheis R, et al. Immunology. 1992 Jul;76(3):433-8. Immunology. 1992. PMID: 1526652 Free PMC article. - Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication.
Kobayashi N, Hamamoto Y, Yamamoto N, Ishii A, Yonehara M, Yonehara S. Kobayashi N, et al. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9620-4. doi: 10.1073/pnas.87.24.9620. Proc Natl Acad Sci U S A. 1990. PMID: 1702216 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical